Table 4.

Subgroup analysis for risk assessment of adiponectin on metabolic syndrome incidence.

	N	OR (95%CI)	I2	P${}_1^{\mathrm{\text{a}}}$	P${}_2^{\mathrm{\text{b}}}$
AGE (YEARS)
< 45	3	0.91(0.87–0.95)	75.1%	0.018
≥45	3	0.95(0.93–0.97)	77.8%	0.011	0.158
GENDER
Male	3	0.85(0.80–0.90)	17.6%	0.297
Female	1	0.96(0.94–0.98)	NA	NA
Mix	2	0.95(0.91–0.99)	0%	0.419	< 0.01
ETHNICITY
Caucasian	2	0.95(0.91–0.99)	0%	0.419
East Asian	4	0.94(0.92–0.96)	83.5%	< 0.001	0.660
FOLLOW-UP (YEARS)
< 4	3	0.94(0.92–0.96)	87.7%	< 0.001
>4	3	0.94(0.90–0.98)	28.6%	0.246	0.979
SAMPLE
Serum	5	0.94(0.92–0.96)	78%	0.001
Plasma	1	0.92(0.89–1.07)	NA	NA	0.360
METHOD
RIA	4	0.94(0.92–0.96)	81.5%	0.001
ELISA	2	0.94(0.86–1.02)	63.4%	0.094	0.954
MeTS INCIDENCE
< 15%	2	0.79(0.69–0.89)	0%	0.508
>15%	4	0.95(0.93–0.96)	67.0%	0.028	0.002
MeTS DEFINITION
NCEP-ATP-III	2	0.95(0.91–0.99)	0%	0.419
Modified NCEP-ATP-III	3	0.94(0.92–0.96)	87.1%	< 0.001
Other definitions	1	0.83(0.67–0.98)	NA	NA	0.341
BMI ADJUSTMENT
Yes	4	0.95(0.93–0.96)	67.0%	0.028
No	2	0.79(0.69–0.89)	0	0.508	0.002
BASELINE ADPQ VALUE (mg/L)
< 9	3	0.85(0.80–0.90)	17.6	0.297
≥9	3	0.96(0.94–0.98)	0	0.663	< 0.01

^aP₁ value represents heterogeneity in subgroups.

^bP₂ value represents heterogeneity across subgroups.

ADPQ, adiponectin; BMI, body mass index; ELISA, enzyme-linked immunoabsorbent assay; MetS, metabolic syndrome; NA, not available; NCEP-ATP-III, National Cholesterol Education Program Adult Treatment Panel III; OR, odds ratio; RIA, radioimmuno assay.